Cargando…

Amyloid-beta peptide and tau protein crosstalk in Alzheimer’s disease

Alzheimer’s disease is a neurodegenerative disease that accounts for most of the 50-million dementia cases worldwide in 2018. A large amount of evidence supports the amyloid cascade hypothesis, which states that amyloid-beta accumulation triggers tau hyperphosphorylation and aggregation in form of n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roda, Alejandro R., Serra-Mir, Gabriel, Montoliu-Gaya, Laia, Tiessler, Lidia, Villegas, Sandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820696/ https://www.ncbi.nlm.nih.gov/pubmed/35017413 http://dx.doi.org/10.4103/1673-5374.332127

Ejemplares similares

Both Amyloid-β Peptide and Tau Protein Are Affected by an Anti-Amyloid-β Antibody Fragment in Elderly 3xTg-AD Mice
por: Roda, Alejandro R., et al.
Publicado: (2020)

Effects of an Aβ-antibody fragment on Aβ aggregation and astrocytic uptake are modulated by apolipoprotein E and J mimetic peptides
por: Montoliu-Gaya, Laia, et al.
Publicado: (2017)

Mechanical Dilution of Beta-amyloid Peptide and Phosphorylated Tau Protein in Alzheimer's Disease: Too Simple to be True?
por: Menéndez González, Manuel
Publicado: (2017)

Neurobiological pathways to Alzheimer’s disease: Amyloid-beta, TAU protein or both?
por: de Paula, Vanessa de Jesus R., et al.
Publicado: (2009)

Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease
por: Milà-Alomà, Marta, et al.
Publicado: (2022)

The Role of Amyloid-Beta and Tau in the Early Pathogenesis of Alzheimer’s Disease
por: Yin, Xiaomin, et al.
Publicado: (2021)

Detection of Alzheimer's disease amyloid beta 1‐42, p‐tau, and t‐tau assays
por: van Harten, Argonde C., et al.
Publicado: (2021)

Production of an anti-Aβ antibody fragment in Pichia pastoris and in vitro and in vivo validation of its therapeutic effect
por: Montoliu-Gaya, Laia, et al.
Publicado: (2017)

Publisher Correction: Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease
por: Milà-Alomà, Marta, et al.
Publicado: (2022)

Amyloid-beta and phosphorylated tau in post-mortem Alzheimer’s disease retinas
por: den Haan, Jurre, et al.
Publicado: (2018)

Electrochemical Immunosensors Developed for Amyloid-Beta and Tau Proteins, Leading Biomarkers of Alzheimer’s Disease
por: Sharma, Abhinav, et al.
Publicado: (2023)

Oxidative stress and the amyloid beta peptide in Alzheimer’s disease
por: Cheignon, C., et al.
Publicado: (2017)

Anti-amyloid-beta to tau-based immunization: developments in immunotherapy for Alzheimer’s disease
por: Lambracht-Washington, Doris, et al.
Publicado: (2013)

Blood Beta-Amyloid and Tau in Down Syndrome: A Comparison with Alzheimer’s Disease
por: Lee, Ni-Chung, et al.
Publicado: (2017)

Amyloid Beta and Phosphorylated Tau-Induced Defective Autophagy and Mitophagy in Alzheimer’s Disease
por: Reddy, P. Hemachandra, et al.
Publicado: (2019)

Whole-brain modeling of the differential influences of amyloid-beta and tau in Alzheimer’s disease
por: Patow, Gustavo, et al.
Publicado: (2023)

Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies
por: Montoliu-Gaya, Laia, et al.
Publicado: (2023)

Blood Biomarkers for Alzheimer’s Disease in Down Syndrome
por: Montoliu-Gaya, Laia, et al.
Publicado: (2021)

Amyloid Beta and Tau Proteins as Therapeutic Targets for Alzheimer's Disease Treatment: Rethinking the Current Strategy
por: Mondragón-Rodríguez, Siddhartha, et al.
Publicado: (2012)

Oxidation of Methionine-35 in Alzheimer’s amyloid-beta peptide and the aggregation of the oxidized peptide
por: Friedemann, Merlin, et al.
Publicado: (2015)

Insulin Resistance as a Link between Amyloid-Beta and Tau Pathologies in Alzheimer’s Disease
por: Mullins, Roger J., et al.
Publicado: (2017)

Amyloid Beta and Tau as Alzheimer’s Disease Blood Biomarkers: Promise From New Technologies
por: Lue, Lih-Fen, et al.
Publicado: (2017)

Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum
por: Milà‐Alomà, Marta, et al.
Publicado: (2020)

JBPOS0101 regulates amyloid beta, tau, and glial cells in an Alzheimer’s disease model
por: Jeong, Jihoon, et al.
Publicado: (2020)

The Correlations Between Plasma Fibrinogen With Amyloid-Beta and Tau Levels in Patients With Alzheimer’s Disease
por: Fan, Dong-Yu, et al.
Publicado: (2021)

Plasma amyloid-beta oligomer and phosphorylated tau: diagnostic tools for progressive Alzheimer’s disease
por: An, Seong Soo A., et al.
Publicado: (2023)

Distinct Molecular Signatures of Amyloid-Beta and Tau in Alzheimer’s Disease Associated with Down Syndrome
por: Ichimata, Shojiro, et al.
Publicado: (2023)

Amyloid Beta and Tau Cooperate to Cause Reversible Behavioral and Transcriptional Deficits in a Model of Alzheimer’s Disease
por: Pickett, Eleanor K., et al.
Publicado: (2019)

Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer’s disease
por: Gangishetti, Umesh, et al.
Publicado: (2018)

Altered filamin A enables amyloid beta-induced tau hyperphosphorylation and neuroinflammation in Alzheimer’s disease
por: Burns, Lindsay H., et al.
Publicado: (2017)

Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition
por: Risacher, Shannon L., et al.
Publicado: (2019)

The novel amyloid-beta peptide aptamer inhibits intracellular amyloid-beta peptide toxicity
por: Wang, Xu, et al.
Publicado: (2013)

Amyloid-beta Alzheimer targets — protein processing, lipid rafts, and amyloid-beta pores
por: Arbor, Sage C., et al.
Publicado: (2016)

Elevated amyloid beta peptides and total tau in cerebrospinal fluid in individuals with Creatine transporter deficiency
por: Rahhal, Samar, et al.
Publicado: (2023)

In Silico Drug Design and Analysis of Dual Amyloid-Beta and Tau Protein-Aggregation Inhibitors for Alzheimer’s Disease Treatment
por: Job, Nisha, et al.
Publicado: (2023)

Intravenous Injection of PHF-Tau Proteins From Alzheimer Brain Exacerbates Neuroinflammation, Amyloid Beta, and Tau Pathologies in 5XFAD Transgenic Mice
por: Houben, Sarah, et al.
Publicado: (2020)

Islet amyloid polypeptide & amyloid beta peptide roles in Alzheimer’s disease: two triggers, one disease
por: Ferreira, Sofia, et al.
Publicado: (2020)

Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer´s Disease Immunotherapy
por: Perez-Garmendia, Roxanna, et al.
Publicado: (2013)

Potential Role of Nanoparticles in Treating the Accumulation of Amyloid-Beta Peptide in Alzheimer’s Patients
por: Abbas, Mohamed
Publicado: (2021)

The relationships between neuroinflammation, beta-amyloid and tau deposition in Alzheimer’s disease: a longitudinal PET study
por: Ismail, Rola, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qc54d3dlnm34g23pe9ed3erqnm